Kimball Electronics, Inc. (KE): Results of Operations and Financial Condition
Kimball Electronics, Inc. (KE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit9918k6302026q410k.htm KIMBALL ELECTRONICS, INC. EX-99.1 Document Exhibit 99.1 KIMBALL ELECTRONICS REPORTS Q4 RESULTS; COMPANY PROVIDES GUIDANCE FOR FISCAL 2027 HIGHLIGHTED BY ORGANIC SALES GROWTH AND ACCRETIVE IMPACT OF THE HELVOET ACQUISITION JASPER, Ind., Augus
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified FY2027 net sales range, organic growth assumptions, Helvoet sales contribution, and adjusted operating income margin guidance, plus balance-sheet improvements (lower debt, strong operating cash flow).
Market read
Guidance plus acquisition contribution and margin range provide a fresh forward earnings framework for KE, likely driving immediate repricing ahead of the conference call.
What to watch
The release notes automotive and industrial vertical declines in Q4; traders may focus on whether those weaknesses persist into FY2027 despite Medical outperformance.
Background
Kimball Electronics filed an 8-K with Exhibit 99.1 covering Q4 and full fiscal year ended June 30, 2026 results and fiscal 2027 guidance, including the Helvoet acquisition impact.
Ticker impact
Kimball Electronics reported Q4 FY2026 results and issued FY2027 guidance, including $1,535-$1,560M net sales and Helvoet sales of about $60M.
Near-term bias higher as guidance implies organic growth plus accretive Helvoet impact, alongside lower debt and strong operating cash flow.
The filing discloses specific Q4 and full-year results plus quantified FY2027 guidance ranges and Helvoet sales contribution, which typically re-rates forward expectations.
Market effects
Signals continued demand strength in medical CDMO/EMS mix, with management expecting Medical to exceed one-third of sales.
Limited direct regional read-through; operations span US and Asia/Europe but guidance is company-wide.
Moderate, as it reflects medical manufacturing outsourcing demand and acquisition-driven growth rather than a macro shock.
Counterpoint
Organic growth is only 3% to 5% and adjusted operating income margin is guided to 4.4% to 4.7%, so upside may be capped if integration costs or customer mix shifts.
Key entities
- issuerKimball Electronics, Inc.
Nasdaq-listed EMS/CDMO provider reporting Q4 FY2026 results and issuing FY2027 guidance.
- acquisition_targetHelvoet Polymer Technologies
Acquired business whose sales contribution is guided at approximately $60M for FY2027.
- executiveRichard D. Phillips
CEO quoted on Q4 performance, balance-sheet strength, and FY2027 outlook.
- executiveJana T. Croom
CFO quoted on balance-sheet condition and FY2027 guidance.
